product name Zonisamide
Description: Zonisamide is a voltage-dependent sodium channel and T-type calcium channel blocker. Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide modifies dopamine (DA) activity, provides protection in ischemia mice models and influences antioxidant systems. Zonisamide attenuates the reduction in striatal contents of DA, its metabolite DOPAC and tyrosine hydroxylase (TH).
References: Exp Neurol. 2010 Feb;221(2):329-34; Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):107-14.
212.23
Formula
C8H8N2O3S
CAS No.
68291-97-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 42 mg/mL (197.9 mM)
Water: <1 mg/mL
Ethanol: 5 mg/mL (23.6 mM)
Solubility (In vivo)
Synonyms
CI-912
other peoduct :
| In Vitro |
In vitro activity: Zonisamide inhibits monoamine oxidase B (MAO-B) activity in vitro with an IC(50) of 25 μM. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Zonisamide modifies dopamine (DA) activity, provides protection in ischemia mice models and influences antioxidant systems. Zonisamide attenuates the reduction in striatal contents of DA, its metabolite DOPAC and tyrosine hydroxylase (TH). Zonisamide (10 and 30 mg/kg) produces antihyperalgesic and antiallodynic effects in a dose-dependent manner, these effects are manifested by elevation of the withdrawal threshold in response to a thermal (plantar test) or mechanical (von Frey) stimulus, respectively.. Zonisamide produces antinociceptive effects against acute thermal and mechanical nociception in non-ligated mice. Zonisamide reduces the cortical infarction volume to 6% from 68% in vehicle-treated controls and the striatal volume to 8% from 78% in rats. Zonisamide also reduces neuronal necrosis in 5 hippocampal regions (the dentate gyrus, CA4, CA3, CA1, and the subiculum) in rats. Zonisamide causes increase in the quantity of EAAC-1 protein in hippocampus and cortex and down regulation of the GABA transporter GAT-1 in rats with hippocampal seizures. Zonisamide inhibits both the 50 mM KCl-evoked hippocampal glutamate release (AUC for 60 min) from 9.2 mM to 5.8 mM in urethane-anaesthetized rats, as well as the stimulatory effects of Ca2+ on KCl-evoked hippocampal glutamate release. |
| Animal model | |
| Formulation & Dosage | |
| References | Exp Neurol. 2010 Feb;221(2):329-34; Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):107-14. |
